Cyprotex
- Company typePrivate
- Founded1999
- HeadquartersMacclesfield, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cyprotex does
Cyprotex is a UK-based contract research organization (CRO) specializing in preclinical ADME-Tox (absorption, distribution, metabolism, excretion, and toxicology) services for the pharmaceutical, biotechnology, chemical, agrochemical, personal care, cosmetics, and household products industries. The company combines robust in vitro experimental methods with in silico modeling to predict human exposure, clinical efficacy, and toxicological outcomes of drug candidates and chemical compounds. Its service portfolio spans four core areas—ADME PK, Toxicology/Preclinical Safety, Physicochemical Profiling, and Modeling & Simulation—supported by proprietary platforms including eCiphr® Cardio (iPS-derived cardiomyocytes on high-throughput microelectrode arrays for cardiotoxicity assessment), eCiphr® Neuro (primary cortical neurons on MEA for neurotoxicity assessment), and CellCiphr® Premier (high-content screening for drug-induced liver injury prediction). The company also offers 3D microtissue models and a New Approach Methodologies (NAMs) resource hub supporting the 3Rs (Replace, Reduce, Refine) of animal testing.
Cyprotex generates revenue through professional service fees for laboratory testing, in vitro assays, and computational modeling under quote-based, project-scoped engagements. Its go-to-market is primarily sales-led via direct engagement with enterprise clients and expert consultation, supplemented by educational webinars and content marketing (newsletters, scientific guides). The company was founded in 1999, headquartered in Macclesfield, UK, operates with 51–100 employees, and was formerly listed on the London Stock Exchange (ticker CRX) before becoming a wholly-owned business unit of Evotec AG, a Frankfurt-listed global drug discovery company. Strategic partnerships include Scientist.com for webinar distribution and co-marketing arrangements with BIOIVT and HUB Organoids.
Cyprotex firmographics
Firmographics- Name
- Cyprotex
- Legal name
- Cyprotex
- Website
- https://cyprotex.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Cyprotex industry classification
Industry- Product category
- Preclinical ADME-Tox Contract Research Services
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
Keywords
Where Cyprotex is headquartered
LocationHeadquarters
- HQ city
- Macclesfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Cyprotex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- ADME-Tox Testing Services: Cyprotex provides contract research services to pharmaceutical, biotech, personal care, cosmetics, household products, chemical, and agrochemical industries. Services include ADME PK, Toxicology/Preclinical Safety, Physicochemical Profiling, and Modeling & Simulation. Revenue is generated through service fees for laboratory testing and analysis.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Cyprotex product offering
Product offeringCore offering
Cyprotex is a contract research organization (CRO) that delivers preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicology) services to pharmaceutical, biotechnology, personal care, cosmetics, household products, chemical, and agrochemical companies. Its offerings include ADME pharmacokinetics, toxicology/preclinical safety testing, physicochemical profiling, and modeling & simulation, supported by proprietary in silico platforms.
Product overview
Cyprotex ADME-Tox Solutions, a subsidiary of Evotec, provides a comprehensive suite of drug discovery and preclinical development services organized around four core service areas: ADME PK, Toxicology/Preclinical Safety, Physicochemical Profiling, and Modeling & Simulation. The company enhances prediction of human exposure, clinical efficacy, and toxicological outcomes by combining in vitro methods with in silico technology. Cyprotex serves pharmaceutical, biotech, personal care, cosmetics, household products, and chemical/agrochemical industries. The portfolio includes proprietary technologies such as eCiphr Cardio (iPS-derived cardiomyocyte cardiotoxicity testing), eCiphr Neuro (neuronal activity monitoring), and CellCiphr Premier (high content screening for DILI prediction), along with 3D microtissue models and NAMs (New Approach Methodologies) for human-relevant testing.
Differentiator
Problem solved
Functional benefit
Brands
- eCiphr®Cardio: Synchronously beating iPS cell derived cardiomyocytes monitored by high throughput microelectrode array (MEA) for cardiotoxicity assessment and disease modelling.
- eCiphr®Neuro
- CellCiphr® Premier
Products and services
- ADME Pharmacokinetics Services
- Toxicology / Preclinical Safety Services
- Physicochemical Profiling Services
- Modeling & Simulation Services
- eCiphrCardio
- eCiphrNeuro
Quantifiable outcome
- Sensitive and specific prediction of DILI (Drug-Induced Liver Injury) through CellCiphr Premier high content screening
- +1 more outcomes
Companies that use Cyprotex
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Cyprotex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Cyprotex partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Scientist.comcoreCyprotex participates in expert webinars hosted by Scientist.com, presenting on New Approach Methodologies (NAMs) for drug discovery and development alongside BIOIVT and HUB Organoids. This partnership positions Cyprotex as an industry educational resource for the life science sector.
- BIOIVTminorCyprotex co-presents with BIOIVT (BioIVT) on human-relevant models and their applications in drug discovery research workflows.
- HUB OrganoidsminorCyprotex co-presents with HUB Organoids on organoid-based screening technologies for drug discovery and development.
- EvoteccoreCyprotex operates as a business unit of Evotec, a global drug discovery and development company. Evotec provides the corporate infrastructure and global reach that supports Cyprotex's ADME-Tox operations.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Cyprotex competitors and assessment
Company assessmentDirect peers
- Pharmaron: Global CRO offering drug discovery and preclinical services including in vitro ADME, DMPK, and safety assessment, overlapping with Cyprotex's preclinical ADME-Tox service lines.
- Eurofins Discovery: Eurofins Discovery offers ADME, pharmacology, and toxicology services in vitro and in silico, directly competing with Cyprotex's ADME PK, physicochemical profiling, and mechanistic toxicology offerings.
- SEKISUI XenoTech: Specialized CRO focused on ADME, drug metabolism, and in vitro toxicology with hepatotoxicity and DILI prediction services, directly comparable to Cyprotex's CellCiphr Premier and ADME PK portfolio.
- Inotiv: Preclinical CRO and research models provider offering toxicology, ADME, and safety pharmacology services, comparable to Cyprotex's preclinical focus and chemistry and safety assessment capabilities.
Broad incumbents
- Fortrea (formerly Labcorp Drug Development): Large CRO spun out of Labcorp with preclinical and early development services including ADME and safety assessment, comparable to Cyprotex's offerings but at significantly greater scale.
- Charles River Laboratories: Global contract research organization with a large preclinical and safety assessment segment that directly overlaps with Cyprotex's ADME-Tox and in vitro toxicology offerings, including cardiovascular and neuro safety services.
- BioReliance (Merck KGaA): Biosafety testing and toxicology services arm of Merck, offering in vitro toxicology and product safety testing that directly competes with Cyprotex's preclinical safety and toxicology services.
- WuXi AppTec: Large global CRO with comprehensive preclinical services including DMPK, toxicology, and in vitro safety assessment, comparable to Cyprotex as a competing provider of preclinical ADME-Tox services.
Emerging players
- CeeTox: Specialized CRO providing in vitro and computational toxicology services for pharma, chemical, and consumer product industries, comparable to Cyprotex's CellCiphr and NAMs offerings.
Others
- BioIVT: Supplier of human biological specimens and in vitro cell models used in drug discovery, co-presenting partner with Cyprotex on NAMs webinars and an enabler of the same preclinical workflow Cyprotex serves.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Cyprotex social profiles
Digital presenceCyprotex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyprotex leadership team
Management profileNumber of profiles
Cyprotex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyprotex M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyprotex
What does Cyprotex do?
Cyprotex is a contract research organization (CRO) that delivers preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicology) services to pharmaceutical, biotechnology, personal care, cosmetics, household products, chemical, and agrochemical companies. Its offerings include ADME pharmacokinetics, toxicology/preclinical safety testing, physicochemical profiling, and modeling & simulation, supported by proprietary in silico platforms.
Is Cyprotex a public or private company?
Cyprotex is a private company. It is classified as corporate owned and is currently operating.
When was Cyprotex founded?
Cyprotex was founded in 1999. It employs 51 to 100 people.
Where is Cyprotex based?
Cyprotex is headquartered in Macclesfield, United Kingdom, in the Europe region.
How does Cyprotex make money?
One revenue line is on record: ADME-Tox Testing Services.
Who are Cyprotex's main competitors?
Direct peers on record are Pharmaron, Eurofins Discovery, SEKISUI XenoTech and Inotiv. Broad incumbents are Fortrea (formerly Labcorp Drug Development), Charles River Laboratories, BioReliance (Merck KGaA) and WuXi AppTec. CeeTox is listed as an emerging player. BioIVT is listed as an others.
Does Cyprotex have an API?
No public API is recorded for Cyprotex.
What industry is Cyprotex in?
Cyprotex's product category is Preclinical ADME-Tox Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK).